TENX.NASDAQTenax Therapeutics, INC

Form 4: TENAX CEO Boosts Stake with Open Market Stock Purchases

Sentiment:

Insider Transaction Report

📋All filings for Tenax Therapeutics, INC
🔒Login to Follow

TENAX Therapeutics CEO Christopher Thomas Giordano acquired additional common stock in open market purchases over three days in November 2025, increasing his direct beneficial ownership.

Summary

  • Christopher Thomas Giordano, CEO and Director of TENAX THERAPEUTICS, INC. (TENX), purchased common stock on three separate dates in November 2025.
  • On November 18, 2025, 1,612 shares were acquired at a weighted average price of $7.7546 per share.
  • On November 19, 2025, an additional 455 shares were acquired at a weighted average price of $7.5091 per share.
  • On November 20, 2025, 538 shares were acquired at a weighted average price of $7.5887 per share.
  • Following these transactions, Mr. Giordano directly beneficially owns 2,605 shares of common stock.
  • The transactions were made pursuant to a Rule 10b5-1(c) plan.
  • Mr. Giordano also holds several stock options, including 157 shares exercisable at $3,152, 125 shares exercisable at $992, 437 shares exercisable at $3.549, 1,250,000 shares exercisable at $5.94, and 1,400,000 shares exercisable at $5.89, all held directly.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the CEO's open market purchases, indicating confidence in the company's valuation and future prospects. Insider buying is generally seen as a bullish signal.

Positives

  • The CEO's open market purchases signal confidence in the company's future prospects and valuation.
  • Transactions were executed under a Rule 10b5-1 plan, indicating a pre-planned investment strategy.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance beyond the vesting schedules of stock options, which are subject to continued employment.

Industry Context

This insider transaction report reflects a direct investment by the CEO, which is generally viewed as a positive signal of management's belief in the company's value, irrespective of broader industry trends. It does not provide specific details on industry performance or competitive positioning.

Stakeholder Impact

  • Shareholders may view the CEO's increased direct ownership as a positive indicator of management alignment with shareholder interests and confidence in the company's future.
  • Employees, particularly those with stock-based compensation, might interpret the insider buying as a sign of stability and potential growth.

Next Steps

  • Continued vesting of stock options for Christopher Thomas Giordano, subject to his continued employment, with various tranches vesting on specific dates through May 2028 and monthly thereafter for certain options.

Key Dates

DateDescription
07/06/202225% of 157 stock options vested and became exercisable.
06/09/202325% of 125 stock options vested and became exercisable.
07/06/202325% of 157 stock options vested and became exercisable.
06/09/202425% of 125 stock options vested and became exercisable.
07/06/202425% of 157 stock options vested and became exercisable.
05/17/202525% of 437 stock options vest and become exercisable.
06/09/202525% of 125 stock options vest and become exercisable.
07/06/202525% of 157 stock options vest and become exercisable.
11/18/2025CEO Christopher Thomas Giordano acquired 1,612 shares of common stock.
11/19/2025CEO Christopher Thomas Giordano acquired 455 shares of common stock.
11/20/2025CEO Christopher Thomas Giordano acquired 538 shares of common stock.
12/10/2025Date exercisable for 1,250,000 stock options.
05/16/202625% of 1,400,000 stock options vest and become exercisable.
05/17/202625% of 437 stock options vest and become exercisable.
06/09/202625% of 125 stock options vest and become exercisable.
05/17/202725% of 437 stock options vest and become exercisable.
05/17/202825% of 437 stock options vest and become exercisable.
07/06/2031Expiration date for 157 stock options.
06/09/2032Expiration date for 125 stock options.
05/17/2034Expiration date for 437 stock options.
12/10/2034Expiration date for 1,250,000 stock options.
05/16/2035Expiration date for 1,400,000 stock options.

Recommendation

hold

The CEO's open market purchases are a positive signal, demonstrating management's confidence in TENAX Therapeutics. While insider buying can be a strong indicator, a Form 4 alone does not provide sufficient comprehensive financial or operational data to warrant a 'buy' or 'strong buy' recommendation. Investors should consider this information as a favorable data point within a broader due diligence process, maintaining a 'hold' position while awaiting further fundamental updates.

Keywords

TENAX Therapeutics, TENX, Insider Buying, Stock Purchase, CEO, Common Stock, Stock Options, Form 4, Beneficial Ownership

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.